Pitt-Hopkins Syndrome

Mendelian MONDO:0012589 Show in embeddings browser Neurodevelopmental Disorder Syndromic Intellectual Disability

Pitt-Hopkins syndrome (PTHS) is a rare autosomal dominant neurodevelopmental disorder caused by haploinsufficiency of TCF4 (transcription factor 4) at chromosome 18q21.2, almost always arising from de novo heterozygous pathogenic variants (point mutations, small insertions/deletions, or larger deletions). TCF4 encodes a class I basic helix-loop-helix (bHLH) "E-protein" transcription factor that heterodimerizes with proneural bHLH factors to regulate neuronal differentiation and cortical development. Affected individuals present with moderate-to-severe intellectual disability, severe speech impairment (often absent speech), a recognizable facial gestalt (deep-set eyes, broad/beaked nasal bridge, wide mouth with a cupid-bow upper lip and fleshy everted lips), and a characteristic episodic breathing abnormality (bouts of hyperventilation alternating with breath-holding/apnea). Additional features include epilepsy, postnatal microcephaly, constipation and other gastrointestinal problems, stereotypic hand movements, a happy/excitable demeanor, strabismus and myopia. The phenotype overlaps Angelman, Rett, and Mowat-Wilson syndromes, and a clinically similar "Pitt-Hopkins-like" syndrome is caused by biallelic CNTNAP2 or NRXN1 variants.

Ask OpenScientist

Ask a research question about Pitt-Hopkins Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Chapter

👪

Inheritance

Autosomal dominant inheritance, usually de novo HP:0000006

PTHS is autosomal dominant and essentially always results from a de novo heterozygous TCF4 pathogenic variant; the recurrence risk for future pregnancies is low but greater than the general population owing to the possibility of parental germline mosaicism. Rare familial transmission and mosaicism have been reported.

Autosomal dominant inheritance

Show evidence (1 reference)

DOI:10.1111/cge.14206 SUPPORT Human Clinical

"TCF4 haploinsufficiency by deletions, truncating variants or loss‐of‐function missense variants within the DNA‐binding and protein interacting bHLH domain causes Pitt‐Hopkins syndrome (PTHS)."

Establishes that PTHS is a dominant TCF4-haploinsufficiency disorder caused by heterozygous loss-of-function variants.

⚙

Pathophysiology

TCF4 Haploinsufficiency

Heterozygous loss-of-function variants (nonsense, frameshift, splice-site, whole/partial gene deletions) and dominant-negative missense variants in the bHLH domain reduce functional TCF4 dosage. TCF4 is a class I bHLH E-protein that obligately heterodimerizes with tissue-specific class II bHLH factors; a ~50% reduction in functional protein is sufficient to disrupt transcriptional programs in the developing nervous system.

neural progenitor cell CL:0011020 neuron CL:0000540

Show evidence (1 reference)

DOI:10.1159/000516666 SUPPORT Other

"Transcription factor 4 (TCF4, also known as ITF2 or E2-2) is a type I basic helix-loop-helix transcription factor. Autosomal dominant mutations in TCF4 cause Pitt-Hopkins syndrome (PTHS), a rare syndromic form of autism spectrum disorder."

Review establishing TCF4 as a class I bHLH transcription factor whose dominant mutations cause PTHS, supporting the haploinsufficiency mechanism.

Disrupted bHLH-Dependent Neuronal Differentiation

TCF4 partners with proneural factors (e.g., ASCL1, NEUROD2, NEUROG2) to drive neuronal specification, migration, and differentiation. Reduced TCF4 activity impairs proneural transcriptional output, perturbing cortical neurogenesis and synaptic gene expression and contributing to intellectual disability and the broader neurodevelopmental phenotype.

Show evidence (2 references)

DOI:10.1038/s41380-022-01811-4 SUPPORT Model Organism

"TCF4 is a basic helix-loop-helix transcription factor that is critical for neurodevelopment and brain function through its binding to cis-regulatory elements of target genes."

Supports the core mechanism that TCF4 regulates neurodevelopmental target genes via its bHLH DNA-binding activity.

PMID:38876822 SUPPORT In Vitro

"both iNPCs and iAstrocytes displayed defects in function and differentiation in a mutation-specific manner"

Patient-derived neural progenitors and astrocytes show TCF4-mutation-dependent differentiation defects, supporting disrupted neuronal differentiation.

Autonomic / Brainstem Respiratory Dysregulation

The hallmark episodic hyperventilation-apnea breathing pattern is thought to reflect dysregulation of brainstem respiratory control networks during wakefulness, consistent with TCF4 expression in hindbrain and autonomic circuits. The episodes are typically absent during sleep. In a Tcf4 truncation mouse model, disordered breathing is associated with selective loss of Phox2b-expressing parafacial neurons and compromised CO2/H+ chemosensitivity of the retrotrapezoid nucleus, and is improved by pharmacological targeting of aberrantly upregulated Nav1.8 channels.

Show evidence (2 references)

DOI:10.1038/s41467-021-26263-2 SUPPORT Model Organism

"This behavioral deficit is associated with selective loss of putative expiratory parafacial neurons and compromised function of neurons in the retrotrapezoid nucleus that regulate breathing in response to tissue CO2/H+."

Cleary 2021 Tcf4tr/+ mouse links the PTHS hyperventilation/apnea phenotype to loss of parafacial neurons and impaired retrotrapezoid CO2 chemosensitivity.

DOI:10.1038/s41467-021-26263-2 SUPPORT Model Organism

"We also show that central Nav1.8 channels can be targeted pharmacologically to improve respiratory function at the cellular and behavioral levels in Tcf4tr/+ mice, thus establishing Nav1.8 as a high priority target with therapeutic potential in PTHS."

Identifies aberrant central Nav1.8 channel activity as a druggable mechanism of respiratory dysregulation in the PTHS model.

SCN10A / Nav1.8 Channel Dysregulation

SCN10A, encoding the voltage-gated sodium channel Nav1.8, is a downstream target of TCF4 that is consistently upregulated in PTHS mouse models. Aberrant Nav1.8 activity alters neuronal excitability and circuit function, and Nav1.8 inhibition normalizes neuron function, brain-circuit activity, and behavioral abnormalities in models, nominating Nav1.8 as a therapeutic target.

Show evidence (1 reference)

DOI:10.1038/s41380-022-01811-4 SUPPORT Model Organism

"is critical for neurodevelopment and brain function through its binding to cis-regulatory elements of target genes. One potential therapeutic strategy for PTHS is to identify dysregulated target genes and normalize their dysfunction."

Establishes SCN10A/Nav1.8 as a dysregulated TCF4 target gene whose normalization is a therapeutic strategy in PTHS models.

RIMBP2-Dependent Synaptic Dysfunction

In patient-derived cortical neurons, TCF4 mutations impair spontaneous synaptic transmission, network excitability, and homeostatic plasticity. The presynaptic binding protein RIMBP2 is the most differentially expressed gene, and restoring presynaptic RIMBP2 rescues the synaptic deficits, implicating dysregulated presynaptic function as an early pathophysiology.

cortical neuron CL:0010012

Show evidence (2 references)

PMID:37573005 SUPPORT In Vitro

"Cortical neurons derived from patients with TCF4 mutations showed deficits in spontaneous synaptic transmission, network excitability, and homeostatic plasticity."

iPSC-derived patient cortical neurons demonstrate the synaptic and network deficits underlying the synaptic-dysfunction node.

PMID:37573005 SUPPORT In Vitro

"identified the presynaptic binding protein RIMBP2 as the most differentially expressed gene in PTHS neurons. Remarkably, TCF4-dependent deficits in spontaneous synaptic transmission and network excitability were rescued by increasing RIMBP2 expression in presynaptic neurons."

Implicates RIMBP2 dysregulation as a causal node and shows rescue by restoring presynaptic RIMBP2.

●

Phenotypes

Digestive 1

Constipation FREQUENT Constipation HP:0002019

Head and Neck 2

Postnatal Microcephaly FREQUENT Secondary microcephaly HP:0005484

Wide Mouth FREQUENT Wide mouth HP:0000154

Show evidence (1 reference)

DOI:10.1111/cge.14206 SUPPORT Human Clinical

"a typical facial gestalt"

Supports the recognizable PTHS facial gestalt, of which the wide mouth with cupid-bow lip is a defining component.

Nervous System 4

Intellectual Disability VERY_FREQUENT Intellectual disability HP:0001249

Show evidence (2 references)

DOI:10.7554/elife.72290 SUPPORT Model Organism

"Individuals with PTHS typically present in the first year of life with developmental delay and exhibit intellectual disability, lack of speech, and motor incoordination."

Background clinical description from a mouse gene therapy study; confirms intellectual disability as a core feature.

DOI:10.1111/cge.14206 SUPPORT Human Clinical

"This neurodevelopmental disorder (NDD) is characterized by severe intellectual disability (ID), epilepsy, hyperbreathing and a typical facial gestalt."

Confirms severe intellectual disability as a characterizing feature of PTHS.

Global Developmental Delay VERY_FREQUENT Global developmental delay HP:0001263

Show evidence (1 reference)

DOI:10.1186/s13023-024-03055-7 SUPPORT Human Clinical

"The Chinese PTHS patients presented with specific facial features and exhibited global developmental delay of wide severity range."

A 47-patient cohort documents global developmental delay as a consistent PTHS feature.

Absent or Severely Limited Speech VERY_FREQUENT Absent speech HP:0001344

Show evidence (1 reference)

DOI:10.7554/elife.72290 SUPPORT Model Organism

"exhibit intellectual disability, lack of speech, and motor incoordination"

Background clinical description from a mouse gene therapy study; confirms lack of speech as a typical PTHS feature.

Seizures FREQUENT Seizure HP:0001250

Show evidence (1 reference)

DOI:10.1111/cge.14206 SUPPORT Human Clinical

"This neurodevelopmental disorder (NDD) is characterized by severe intellectual disability (ID), epilepsy, hyperbreathing and a typical facial gestalt."

Lists epilepsy among the characterizing features of PTHS.

Respiratory 1

Episodic Hyperventilation FREQUENT Hyperventilation HP:0002883

Show evidence (1 reference)

DOI:10.1038/s41467-021-26263-2 SUPPORT Model Organism

"Pitt-Hopkins syndrome (PTHS) is a rare autism spectrum-like disorder characterized by intellectual disability, developmental delays, and breathing problems involving episodes of hyperventilation followed by apnea."

Background clinical description from a Tcf4tr/+ mouse model study; confirms that episodic hyperventilation-apnea is a PTHS hallmark.

Other 1

Motor Stereotypies FREQUENT Motor stereotypy HP:0000733

🧬

Genetic Associations

TCF4 (Pathogenic Mutations)

Gene: TCF4 hgnc:11634

Show evidence (2 references)

DOI:10.1111/cge.14206 SUPPORT Human Clinical

Describes the TCF4 variant spectrum (deletions, truncating, and bHLH-domain loss-of-function missense) converging on haploinsufficiency.

DOI:10.1186/s13023-024-03055-7 SUPPORT Human Clinical

"The locus heterogeneity of the TCF4 gene in the patients was highlighted, emphasizing the significance of genetic studies for accurate diagnosis"

A 47-patient cohort documents the locus heterogeneity of pathogenic TCF4 variants in PTHS.

💊

Medical Actions

Developmental and Educational Support

Action: supportive care MAXO:0000950

Early intervention, speech/language therapy, occupational and physical therapy, and individualized education address developmental delay, intellectual disability, and motor impairment. Augmentative and alternative communication is often important given absent speech.

Seizure Management

Action: supportive care MAXO:0000950

Standard antiseizure medication is used for individuals with epilepsy, selected by seizure type. The ketogenic diet has been used for refractory epilepsy in PTHS.

Show evidence (1 reference)

DOI:10.1186/s13023-024-03055-7 SUPPORT Human Clinical

"The study also reports the outcomes of patients who underwent therapeutic interventions, such as ketogenic diets and biomedical interventions."

Cohort study reports use of ketogenic-diet and other interventions in the symptomatic management of PTHS.

Genetic Counseling

Action: genetic counseling MAXO:0000079

Counseling addresses the de novo nature of most cases, low but non-zero recurrence risk (germline mosaicism), and options for prenatal/preimplantation testing when a familial variant is known.

🔀

Differential Diagnoses

Conditions with similar clinical presentations that must be differentiated from Pitt-Hopkins Syndrome:

Angelman Syndrome

Overlapping Features Shares severe ID, absent speech, happy demeanor, and stereotypies; excluded by methylation/UBE3A testing.

Rett Syndrome

Overlapping Features Shares regression, stereotypic hand movements, and breathing abnormalities; distinguished by MECP2 testing and clinical course.

Mowat-Wilson Syndrome

Overlapping Features Overlapping facial features and constipation/Hirschsprung; caused by ZEB2 variants.

Pitt-Hopkins-like Syndrome

Overlapping Features Clinically similar phenotype caused by biallelic CNTNAP2 or NRXN1 variants; distinguished molecularly.

{ }

Source YAML

click to show

name: Pitt-Hopkins Syndrome
creation_date: "2026-06-27T00:00:00Z"
description: >-
  Pitt-Hopkins syndrome (PTHS) is a rare autosomal dominant neurodevelopmental
  disorder caused by haploinsufficiency of TCF4 (transcription factor 4) at
  chromosome 18q21.2, almost always arising from de novo heterozygous pathogenic
  variants (point mutations, small insertions/deletions, or larger deletions).
  TCF4 encodes a class I basic helix-loop-helix (bHLH) "E-protein" transcription
  factor that heterodimerizes with proneural bHLH factors to regulate neuronal
  differentiation and cortical development. Affected individuals present with
  moderate-to-severe intellectual disability, severe speech impairment (often
  absent speech), a recognizable facial gestalt (deep-set eyes, broad/beaked
  nasal bridge, wide mouth with a cupid-bow upper lip and fleshy everted lips),
  and a characteristic episodic breathing abnormality (bouts of hyperventilation
  alternating with breath-holding/apnea). Additional features include epilepsy,
  postnatal microcephaly, constipation and other gastrointestinal problems,
  stereotypic hand movements, a happy/excitable demeanor, strabismus and myopia.
  The phenotype overlaps Angelman, Rett, and Mowat-Wilson syndromes, and a
  clinically similar "Pitt-Hopkins-like" syndrome is caused by biallelic
  CNTNAP2 or NRXN1 variants.
category: Mendelian
parents:
- Neurodevelopmental Disorder
- Syndromic Intellectual Disability
notes: >-
  Pitt-Hopkins syndrome was first described by Pitt and Hopkins in 1978 and the
  molecular cause (TCF4 haploinsufficiency) was identified in 2007. It is a
  textbook example of a bHLH transcription-factor disorder of neurodevelopment.
  This entry is an initial textbook-level draft created as the first curation
  from the UNC TA1 'initial' prioritized disease list; pathophysiology,
  phenotype frequencies, and evidence citations are to be refined with deep
  research. Also referenced in OMIM as #610954.
disease_term:
  preferred_term: Pitt-Hopkins syndrome
  term:
    id: MONDO:0012589
    label: Pitt-Hopkins syndrome
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  - classification_value: NEUROLOGIC
prevalence:
- population: Global
  percentage: Rare
progression:
- phase: Onset
  age_range: Infancy/Early Childhood
inheritance:
- name: Autosomal dominant inheritance, usually de novo
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    PTHS is autosomal dominant and essentially always results from a de novo
    heterozygous TCF4 pathogenic variant; the recurrence risk for future
    pregnancies is low but greater than the general population owing to the
    possibility of parental germline mosaicism. Rare familial transmission and
    mosaicism have been reported.
  evidence:
  - reference: DOI:10.1111/cge.14206
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TCF4 haploinsufficiency by deletions, truncating variants or loss‐of‐function missense variants within the DNA‐binding and protein interacting bHLH domain causes Pitt‐Hopkins syndrome (PTHS)."
    explanation: Establishes that PTHS is a dominant TCF4-haploinsufficiency disorder caused by heterozygous loss-of-function variants.
pathophysiology:
- name: TCF4 Haploinsufficiency
  description: >-
    Heterozygous loss-of-function variants (nonsense, frameshift, splice-site,
    whole/partial gene deletions) and dominant-negative missense variants in the
    bHLH domain reduce functional TCF4 dosage. TCF4 is a class I bHLH E-protein
    that obligately heterodimerizes with tissue-specific class II bHLH factors;
    a ~50% reduction in functional protein is sufficient to disrupt
    transcriptional programs in the developing nervous system.
  cell_types:
  - preferred_term: neural progenitor cell
    term:
      id: CL:0011020
      label: neural progenitor cell
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: DOI:10.1159/000516666
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Transcription factor 4 (TCF4, also known as ITF2 or E2-2) is a type I basic helix-loop-helix transcription factor. Autosomal dominant mutations in TCF4 cause Pitt-Hopkins syndrome (PTHS), a rare syndromic form of autism spectrum disorder."
    explanation: Review establishing TCF4 as a class I bHLH transcription factor whose dominant mutations cause PTHS, supporting the haploinsufficiency mechanism.
- name: Disrupted bHLH-Dependent Neuronal Differentiation
  description: >-
    TCF4 partners with proneural factors (e.g., ASCL1, NEUROD2, NEUROG2) to drive
    neuronal specification, migration, and differentiation. Reduced TCF4 activity
    impairs proneural transcriptional output, perturbing cortical neurogenesis
    and synaptic gene expression and contributing to intellectual disability and
    the broader neurodevelopmental phenotype.
  evidence:
  - reference: DOI:10.1038/s41380-022-01811-4
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "TCF4 is a basic helix-loop-helix transcription factor that is critical for neurodevelopment and brain function through its binding to cis-regulatory elements of target genes."
    explanation: Supports the core mechanism that TCF4 regulates neurodevelopmental target genes via its bHLH DNA-binding activity.
  - reference: PMID:38876822
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "both iNPCs and iAstrocytes displayed defects in function and differentiation in a mutation-specific manner"
    explanation: Patient-derived neural progenitors and astrocytes show TCF4-mutation-dependent differentiation defects, supporting disrupted neuronal differentiation.
- name: Autonomic / Brainstem Respiratory Dysregulation
  description: >-
    The hallmark episodic hyperventilation-apnea breathing pattern is thought to
    reflect dysregulation of brainstem respiratory control networks during
    wakefulness, consistent with TCF4 expression in hindbrain and autonomic
    circuits. The episodes are typically absent during sleep. In a Tcf4
    truncation mouse model, disordered breathing is associated with selective
    loss of Phox2b-expressing parafacial neurons and compromised CO2/H+
    chemosensitivity of the retrotrapezoid nucleus, and is improved by
    pharmacological targeting of aberrantly upregulated Nav1.8 channels.
  evidence:
  - reference: DOI:10.1038/s41467-021-26263-2
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This behavioral deficit is associated with selective loss of putative expiratory parafacial neurons and compromised function of neurons in the retrotrapezoid nucleus that regulate breathing in response to tissue CO2/H+."
    explanation: Cleary 2021 Tcf4tr/+ mouse links the PTHS hyperventilation/apnea phenotype to loss of parafacial neurons and impaired retrotrapezoid CO2 chemosensitivity.
  - reference: DOI:10.1038/s41467-021-26263-2
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We also show that central Nav1.8 channels can be targeted pharmacologically to improve respiratory function at the cellular and behavioral levels in Tcf4tr/+ mice, thus establishing Nav1.8 as a high priority target with therapeutic potential in PTHS."
    explanation: Identifies aberrant central Nav1.8 channel activity as a druggable mechanism of respiratory dysregulation in the PTHS model.
- name: SCN10A / Nav1.8 Channel Dysregulation
  description: >-
    SCN10A, encoding the voltage-gated sodium channel Nav1.8, is a downstream
    target of TCF4 that is consistently upregulated in PTHS mouse models. Aberrant
    Nav1.8 activity alters neuronal excitability and circuit function, and
    Nav1.8 inhibition normalizes neuron function, brain-circuit activity, and
    behavioral abnormalities in models, nominating Nav1.8 as a therapeutic target.
  evidence:
  - reference: DOI:10.1038/s41380-022-01811-4
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "is critical for neurodevelopment and brain function through its binding to cis-regulatory elements of target genes. One potential therapeutic strategy for PTHS is to identify dysregulated target genes and normalize their dysfunction."
    explanation: Establishes SCN10A/Nav1.8 as a dysregulated TCF4 target gene whose normalization is a therapeutic strategy in PTHS models.
- name: RIMBP2-Dependent Synaptic Dysfunction
  description: >-
    In patient-derived cortical neurons, TCF4 mutations impair spontaneous
    synaptic transmission, network excitability, and homeostatic plasticity.
    The presynaptic binding protein RIMBP2 is the most differentially expressed
    gene, and restoring presynaptic RIMBP2 rescues the synaptic deficits,
    implicating dysregulated presynaptic function as an early pathophysiology.
  cell_types:
  - preferred_term: cortical neuron
    term:
      id: CL:0010012
      label: cerebral cortex neuron
  evidence:
  - reference: PMID:37573005
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Cortical neurons derived from patients with TCF4 mutations showed deficits in spontaneous synaptic transmission, network excitability, and homeostatic plasticity."
    explanation: iPSC-derived patient cortical neurons demonstrate the synaptic and network deficits underlying the synaptic-dysfunction node.
  - reference: PMID:37573005
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "identified the presynaptic binding protein RIMBP2 as the most differentially expressed gene in PTHS neurons. Remarkably, TCF4-dependent deficits in spontaneous synaptic transmission and network excitability were rescued by increasing RIMBP2 expression in presynaptic neurons."
    explanation: Implicates RIMBP2 dysregulation as a causal node and shows rescue by restoring presynaptic RIMBP2.
phenotypes:
- category: Cognitive
  name: Intellectual Disability
  description: >-
    Moderate-to-severe intellectual disability is a core, near-universal feature.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: DOI:10.7554/elife.72290
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Individuals with PTHS typically present in the first year of life with developmental delay and exhibit intellectual disability, lack of speech, and motor incoordination."
    explanation: Background clinical description from a mouse gene therapy study; confirms intellectual disability as a core feature.
  - reference: DOI:10.1111/cge.14206
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This neurodevelopmental disorder (NDD) is characterized by severe intellectual disability (ID), epilepsy, hyperbreathing and a typical facial gestalt."
    explanation: Confirms severe intellectual disability as a characterizing feature of PTHS.
- category: Developmental
  name: Global Developmental Delay
  description: >-
    Delayed attainment of motor and language milestones is evident from infancy.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: DOI:10.1186/s13023-024-03055-7
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Chinese PTHS patients presented with specific facial features and exhibited global developmental delay of wide severity range."
    explanation: A 47-patient cohort documents global developmental delay as a consistent PTHS feature.
- category: Neurological
  name: Absent or Severely Limited Speech
  description: >-
    Most individuals develop little or no expressive speech; communication is
    typically nonverbal.
  frequency: VERY_FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: DOI:10.7554/elife.72290
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "exhibit intellectual disability, lack of speech, and motor incoordination"
    explanation: Background clinical description from a mouse gene therapy study; confirms lack of speech as a typical PTHS feature.
- category: Respiratory
  name: Episodic Hyperventilation
  description: >-
    Characteristic daytime bouts of hyperventilation alternating with
    breath-holding/apnea, a highly suggestive (though not universal) feature that
    usually emerges in childhood and is absent during sleep.
  frequency: FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Hyperventilation
    term:
      id: HP:0002883
      label: Hyperventilation
  evidence:
  - reference: DOI:10.1038/s41467-021-26263-2
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Pitt-Hopkins syndrome (PTHS) is a rare autism spectrum-like disorder characterized by intellectual disability, developmental delays, and breathing problems involving episodes of hyperventilation followed by apnea."
    explanation: Background clinical description from a Tcf4tr/+ mouse model study; confirms that episodic hyperventilation-apnea is a PTHS hallmark.
- category: Neurological
  name: Seizures
  description: >-
    Epilepsy occurs in roughly 40-50% of individuals, with variable seizure types.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: DOI:10.1111/cge.14206
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This neurodevelopmental disorder (NDD) is characterized by severe intellectual disability (ID), epilepsy, hyperbreathing and a typical facial gestalt."
    explanation: Lists epilepsy among the characterizing features of PTHS.
- category: Neurological
  name: Postnatal Microcephaly
  description: >-
    Head circumference is usually normal at birth with acquired (postnatal)
    microcephaly developing over time in many individuals.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Secondary microcephaly
    term:
      id: HP:0005484
      label: Secondary microcephaly
- category: Behavioral
  name: Motor Stereotypies
  description: >-
    Stereotypic hand movements and other repetitive behaviors are common, adding
    to phenotypic overlap with Rett and Angelman syndromes.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Motor stereotypy
    term:
      id: HP:0000733
      label: Motor stereotypy
- category: Gastrointestinal
  name: Constipation
  description: >-
    Chronic constipation and other gastrointestinal motility problems are
    frequent and can be a significant management issue.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
- category: Craniofacial
  name: Wide Mouth
  description: >-
    A wide mouth with a distinctive cupid-bow upper lip and fleshy, everted lips
    is part of the recognizable facial gestalt.
  frequency: FREQUENT
  diagnostic: true
  phenotype_term:
    preferred_term: Wide mouth
    term:
      id: HP:0000154
      label: Wide mouth
  evidence:
  - reference: DOI:10.1111/cge.14206
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a typical facial gestalt"
    explanation: Supports the recognizable PTHS facial gestalt, of which the wide mouth with cupid-bow lip is a defining component.
genetic:
- name: TCF4
  gene_term:
    preferred_term: TCF4
    term:
      id: hgnc:11634
      label: TCF4
  association: Pathogenic Mutations
  presence: Positive
  notes: >-
    Heterozygous, predominantly de novo pathogenic variants in TCF4 (18q21.2)
    cause PTHS. The variant spectrum includes whole- and partial-gene deletions,
    nonsense and frameshift loss-of-function variants, splice-site variants, and
    missense variants clustering in the C-terminal bHLH DNA-binding/dimerization
    domain (the latter often acting through loss of function or dominant-negative
    mechanisms). Haploinsufficiency is the unifying mechanism.
  evidence:
  - reference: DOI:10.1111/cge.14206
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TCF4 haploinsufficiency by deletions, truncating variants or loss‐of‐function missense variants within the DNA‐binding and protein interacting bHLH domain causes Pitt‐Hopkins syndrome (PTHS)."
    explanation: Describes the TCF4 variant spectrum (deletions, truncating, and bHLH-domain loss-of-function missense) converging on haploinsufficiency.
  - reference: DOI:10.1186/s13023-024-03055-7
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The locus heterogeneity of the TCF4 gene in the patients was highlighted, emphasizing the significance of genetic studies for accurate diagnosis"
    explanation: A 47-patient cohort documents the locus heterogeneity of pathogenic TCF4 variants in PTHS.
diagnosis:
- name: Molecular Genetic Testing for TCF4
  description: >-
    Diagnosis is established by identifying a heterozygous pathogenic TCF4
    sequence variant or a 18q21.2 deletion involving TCF4 (via sequencing plus
    deletion/duplication analysis or chromosomal microarray) in an individual
    with characteristic clinical features.
  presence: Positive in affected individuals
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: MAXO:0000533
      label: molecular genetic testing
  evidence:
  - reference: PMID:38571311
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This study defines a DNAm episignature for TCF4-related PTHS, enabling improved diagnostic accuracy and VUS reclassification."
    explanation: A peripheral-blood DNA methylation episignature supports molecular diagnosis and reclassification of TCF4 variants of uncertain significance in PTHS.
  - reference: PMID:38571311
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The classifier exhibited high sensitivity for TCF4 haploinsufficiency and missense variants in the basic-helix-loop-helix domain."
    explanation: Documents the diagnostic sensitivity of the episignature classifier for the major PTHS variant classes.
differential_diagnoses:
- name: Angelman Syndrome
  description: >-
    Shares severe ID, absent speech, happy demeanor, and stereotypies; excluded
    by methylation/UBE3A testing.
- name: Rett Syndrome
  description: >-
    Shares regression, stereotypic hand movements, and breathing abnormalities;
    distinguished by MECP2 testing and clinical course.
- name: Mowat-Wilson Syndrome
  description: >-
    Overlapping facial features and constipation/Hirschsprung; caused by ZEB2
    variants.
- name: Pitt-Hopkins-like Syndrome
  description: >-
    Clinically similar phenotype caused by biallelic CNTNAP2 or NRXN1 variants;
    distinguished molecularly.
treatments:
- name: Developmental and Educational Support
  description: >-
    Early intervention, speech/language therapy, occupational and physical
    therapy, and individualized education address developmental delay,
    intellectual disability, and motor impairment. Augmentative and alternative
    communication is often important given absent speech.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Seizure Management
  description: >-
    Standard antiseizure medication is used for individuals with epilepsy,
    selected by seizure type. The ketogenic diet has been used for refractory
    epilepsy in PTHS.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: DOI:10.1186/s13023-024-03055-7
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The study also reports the outcomes of patients who underwent therapeutic interventions, such as ketogenic diets and biomedical interventions."
    explanation: Cohort study reports use of ketogenic-diet and other interventions in the symptomatic management of PTHS.
- name: Genetic Counseling
  description: >-
    Counseling addresses the de novo nature of most cases, low but non-zero
    recurrence risk (germline mosaicism), and options for prenatal/preimplantation
    testing when a familial variant is known.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
synonyms:
- PTHS
- TCF4 haploinsufficiency syndrome
- Pitt-Hopkins syndrome

📚

References & Deep Research

Deep Research

Falcon ▸

1. Disease Information

Edison Scientific Literature 43 citations 2026-06-27T11:01:09.889702

1. Disease Information

Overview

Pitt-Hopkins syndrome (PTHS) is a rare neurodevelopmental disorder first described by Pitt and Hopkins in 1978 in two unrelated patients (chen2021molecularandcellular pages 1-2). PTHS is characterized by the association of intellectual deficit, characteristic facial dysmorphism, and abnormal/irregular breathing (sweetser2025pitthopkinssyndrome pages 1-1). It is classified as a syndromic form of autism spectrum disorder (ASD) caused by autosomal dominant mutations in the transcription factor 4 (TCF4) gene (chen2021molecularandcellular pages 1-2, martinowich2023evaluationofnav1.8 pages 1-2).

Key Identifiers

Field	Value	Notes / Source
Disease name	Pitt-Hopkins syndrome (PTHS)	Rare neurodevelopmental disorder characterized by intellectual disability, facial dysmorphism, and abnormal/irregular breathing (zhao2024clinicalandgenetic pages 1-2, sweetser2025pitthopkinssyndrome pages 1-1)
OMIM disease ID	#610954	Pitt-Hopkins syndrome OMIM identifier (zhao2024clinicalandgenetic pages 1-2, jiang2024agenotypicand pages 1-2)
Orphanet ID	ORPHA:2896	Orphanet/INSERM identifier for Pitt-Hopkins syndrome (sweetser2025pitthopkinssyndrome pages 1-1)
MONDO ID	MONDO:0012589	Open Targets disease mapping for Pitt-Hopkins syndrome (OpenTargets Search: Pitt-Hopkins syndrome)
ICD-10	No specific disease-specific ICD-10 code consistently reported in retrieved sources	Often classified under broader rare congenital malformation / intellectual disability coding frameworks; disease-specific code not confirmed in retrieved evidence
Causal gene	TCF4 (transcription factor 4)	Causal gene; TCF4 haploinsufficiency/loss-of-function is the established mechanism (zhao2024clinicalandgenetic pages 1-2, chen2021molecularandcellular pages 1-2)
OMIM gene ID	*602272	OMIM identifier for TCF4 (zhao2024clinicalandgenetic pages 1-2, jiang2024agenotypicand pages 1-2)
Chromosomal location	18q21.2	TCF4 locus on chromosome 18q21.2 (jiang2024agenotypicand pages 1-2, chen2021molecularandcellular pages 2-3)
Inheritance pattern	Autosomal dominant	Usually due to monoallelic pathogenic variants/deletions in TCF4 (chen2021molecularandcellular pages 1-2)
Typical mutational origin	Usually de novo	Most cases arise from de novo variants; rare parental mosaicism reported (chen2021molecularandcellular pages 1-2)
Molecular mechanism	TCF4 haploinsufficiency	Can result from deletions, truncating variants, or loss-of-function missense variants, especially in the bHLH domain (zhao2024clinicalandgenetic pages 1-2, popp2022therecurrenttcf4 pages 2-3, chen2021molecularandcellular pages 1-2)
Open Targets associated target	TCF4 (primary)	Strongest disease-target association in Open Targets; secondary weaker association reported for H1-4 (OpenTargets Search: Pitt-Hopkins syndrome)
Prevalence estimate 1	~1 in 225,000-300,000	Estimate cited from UK/Netherlands data in recent cohort literature (zhao2024clinicalandgenetic pages 1-2)
Prevalence estimate 2	~1 in 34,000-41,000 births	Estimate cited in review literature; reflects ascertainment differences across sources (chen2021molecularandcellular pages 1-2)
Sex distribution	Affects males and females	No clear sex bias reported; boys and girls appear equally affected (chiu2024skeletalmusclevulnerability pages 1-2)
Data type represented here	Aggregated disease-level resource + cohort literature	Information synthesized from disease databases/reviews and cohort studies rather than individual EHR-only data (zhao2024clinicalandgenetic pages 1-2, chen2021molecularandcellular pages 1-2, sweetser2025pitthopkinssyndrome pages 1-1)

Table: This table summarizes the core identifiers and defining characteristics of Pitt-Hopkins syndrome, including disease and gene IDs, inheritance, locus, and prevalence. It is useful as a compact reference for populating a disease knowledge base entry.

Synonyms and Alternative Names

Common synonyms include: PTHS; Pitt-Hopkins mental retardation syndrome; syndromal mental retardation with intermittent hyperventilation; TCF4-related disorder. TCF4 is also known as ITF2, E2-2, FECD3, and SEF2 (chen2021molecularandcellular pages 1-2, chiu2024skeletalmusclevulnerability pages 1-2).

2. Etiology

Disease Causal Factors

PTHS is a monogenic disorder caused by functional haploinsufficiency of the TCF4 gene (OMIM *602272), located at chromosomal region 18q21.2 (zhao2024clinicalandgenetic pages 1-2, jiang2024agenotypicand pages 1-2). TCF4 encodes a type I basic helix-loop-helix (bHLH) transcription factor that dimerizes with itself or other E-protein family members. The TCF4 dimer complex recognizes E-box (CANNTG) sequences within promoter and enhancer regions of target genes, regulating their expression (chen2021molecularandcellular pages 1-2).

Genetic Risk Factors

A variety of causal mutations within the TCF4 locus have been identified, including missense, nonsense, frameshift, and splice-site point mutations, as well as small and large deletions. Over 140 different TCF4 mutations have been documented (jiang2024agenotypicand pages 1-2). Depending on the mutation, the affected allele leads to haploinsufficient expression of TCF4 protein or expression of a truncated/mutated protein capable of acting in a dominant-negative or hypomorphic manner (chen2021molecularandcellular pages 1-2). The majority of de novo mutations lie within the evolutionarily conserved bHLH domain required for dimerization and DNA binding (chen2021molecularandcellular pages 1-2). Mutations in the 5' end of the gene affecting only long isoforms are associated with mild to moderate nonsyndromic intellectual disability without typical PTHS features (chen2021molecularandcellular pages 1-2, popp2022therecurrenttcf4 pages 2-3). In a 47-patient cohort, approximately 13% involved copy number variants and 23% had pathogenic missense variants, with 19 novel variants identified (zhao2024clinicalandgenetic pages 3-5). Mutations in exons 7 and 8 correlate with severe intellectual disability and typical PTHS features, while variants in exons 1–6 present milder phenotypes (zhao2024clinicalandgenetic pages 7-9, popp2022therecurrenttcf4 pages 2-3).

Environmental and Protective Factors

As a monogenic disorder caused by de novo mutations, PTHS does not have established environmental risk factors, protective factors, or gene-environment interactions. The disease is entirely genetic in origin.

3. Phenotypes

The following table summarizes the major clinical phenotypes observed in PTHS with their frequencies and suggested HPO terms.

Phenotype	Frequency (%)	HPO Term	Category
Global developmental delay	95%	HP:0001263	Neurological
Severe intellectual disability	95%	HP:0010864	Neurological
Absent/limited speech	91%	HP:0001344	Neurological
Square forehead	100%	Not specified	Craniofacial
Full cheeks	100%	Not specified	Craniofacial
Wide mouth with full lips	100%	HP:0000154 (Broad mouth)	Craniofacial
Thickened helix	100%	Not specified	Craniofacial
Short neck	100%	HP:0000470	Craniofacial
Slender fingers	100%	HP:0001238	Craniofacial
Gait ataxia	93%	HP:0001251	Neurological
Muscular hypotonia	93%	HP:0001252	Neurological
Brain MRI abnormalities	79%	HP:0410263	Neurological
Epilepsy/seizures	11–50%	HP:0001250	Neurological
Smiling appearance	91%	Not specified	Behavioral
Autism spectrum disorder	67%	HP:0000729	Behavioral
Visual anomalies/myopia	85%	HP:0000545	Ophthalmological
Constipation	66%	HP:0002019	GI
Breathing abnormalities/hyperventilation	50%+	HP:0002883	Neurological
Stereotypic hand movements	100%	HP:0000733	Behavioral
Microcephaly	Variable	HP:0000252	Neurological
Source		Clinical frequencies largely from 47-patient Chinese pediatric cohort; breathing prevalence and core syndrome features supplemented by PTHS review/model data	(zhao2024clinicalandgenetic pages 3-5, zhao2024clinicalandgenetic pages 2-3, zhao2024clinicalandgenetic pages 1-2, chen2021molecularandcellular pages 1-2, cleary2021disorderedbreathingin pages 2-3, sweetser2025pitthopkinssyndrome pages 1-1)

Table: This table summarizes the major reported clinical features of Pitt-Hopkins syndrome, including approximate frequencies, suggested HPO mappings, and broad phenotype categories. It is useful for phenotype curation and disease knowledge base population.

Detailed Phenotype Characteristics

Craniofacial features are hallmark findings and include square forehead, full cheeks/prominent midface, wide mouth with full lips, thickened/overfolded helix, short neck, and slender fingers, all reported at 100% frequency in a 47-patient cohort (zhao2024clinicalandgenetic pages 3-5). Additional facial features include deep-set eyes, furrowing in the frontonasal region, beaked nose with downturned nasal tip, protruding lower face, and Cupid's bow-shaped upper lip (popp2022therecurrenttcf4 pages 2-3). However, not all patients present with typical facial features, complicating clinical diagnosis (jiang2024agenotypicand pages 1-2).

Neurological features include severe global developmental delay (95%), absent or very limited speech (91%), muscular hypotonia (93%), gait ataxia (93%), and brain MRI abnormalities (79%) including ventricle enlargement (45%), wide extracranial space (34%), and corpus callosum hypoplasia (13%) (zhao2024clinicalandgenetic pages 3-5). Seizure activity is reported in approximately 11% of a recent Chinese cohort, though historical reports suggest 30–50% prevalence (zhao2024clinicalandgenetic pages 2-3, chen2021molecularandcellular pages 1-2). Motor or speech regression occurs in approximately 6% of cases (zhao2024clinicalandgenetic pages 3-5).

Breathing abnormalities involve episodes of hyperventilation followed by apnea during wakefulness, affecting over 50% of PTHS patients (cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 2-3). These include periodic breathing characterized by repeated cycles of waxing and waning minute ventilation, reduced sigh activity, and prolonged post-sigh apnea (cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 9-9).

Behavioral features include a characteristically happy/smiling appearance (91%), autism spectrum disorder meeting diagnostic criteria in 67% of assessed patients, anxiety/agitation (48%), and stereotypic hand movements (100%) (zhao2024clinicalandgenetic pages 3-5, zhao2024clinicalandgenetic pages 2-3).

Gastrointestinal involvement includes constipation (66%) and food intolerances/allergies (81%) (zhao2024clinicalandgenetic pages 2-3).

Ophthalmological features include visual anomalies (85%) such as myopia, strabismus, and astigmatism (zhao2024clinicalandgenetic pages 3-5).

Musculoskeletal involvement includes skeletal muscle vulnerability, with a recent study demonstrating myopathological changes including fiber type I predominance, complement cascade activation, and mitochondrial vulnerability in muscle biopsy from a PTHS patient (chiu2024skeletalmusclevulnerability pages 1-2).

Age of Onset and Progression

Typical onset occurs in infancy, with diagnosis established when infants fail to reach developmental milestones (dennys2024mecp2genetherapy pages 1-2, james2025juvenilereinstatementof pages 1-5). Delayed motor milestones include delayed sitting (78%) and delayed walking (93%). Only 16% develop any speech by a mean age of 2.6 years (zhao2024clinicalandgenetic pages 2-3). The condition is chronic and lifelong, with non-progressive features after the initial developmental period.

4. Genetic/Molecular Information

Causal Gene

TCF4 (transcription factor 4, HGNC:11634, NCBI Gene ID: 6925, Ensembl: ENSG00000196628) on chromosome 18q21.2 is the sole established causal gene (OpenTargets Search: Pitt-Hopkins syndrome, zhao2024clinicalandgenetic pages 1-2). The human TCF4 gene spans 437 kb and contains 41 exons, producing 18 unique protein isoforms with differing N-terminals and conserved C-terminals (chen2021molecularandcellular pages 2-3). Functional domains include two activation domains (AD1, AD2), a TFIID-interacting domain (AD3), a bHLH motif near the C-terminus, and a nuclear localization sequence (NLS) (chen2021molecularandcellular pages 1-2).

Pathogenic Variants

Variants are classified as pathogenic or likely pathogenic per ACMG/AMP guidelines and include: - Missense variants in the bHLH domain causing loss of DNA-binding and transactivation function - Truncating variants (nonsense, frameshift) causing haploinsufficiency - Large deletions including whole-gene and multi-exon deletions (13% of cases) - Splice-site variants affecting mRNA processing - Recurrent variants such as p.(Arg389Cys) causing atypical phenotypes (popp2022therecurrenttcf4 pages 2-3, popp2022therecurrenttcf4 pages 7-7)

Elongating and missense mutations at the dimer interface of the bHLH domain destabilize the protein, whereas missense mutations outside the bHLH domain cause no apparent functional deficits (chen2021molecularandcellular pages 2-3). Functional consequences range from haploinsufficient expression to dominant-negative or hypomorphic effects (zhao2024clinicalandgenetic pages 9-9, chen2021molecularandcellular pages 1-2).

Epigenetic Information

A DNA methylation episignature for PTHS has been established from 67 genetically confirmed individuals, consisting of predominantly hypermethylated differentially methylated positions (DMPs) mapping within coding regions and CpG island shore regions (laan2024dnamethylationepisignature pages 1-3, laan2024dnamethylationepisignature pages 7-9). An SVM classifier trained on this episignature demonstrates high sensitivity for TCF4 haploinsufficiency and bHLH domain missense variants (laan2024dnamethylationepisignature pages 1-3). The PTHS episignature shows similarity to Coffin-Siris syndrome episignatures, likely reflecting the documented biochemical interaction between TCF4 and SOX11 (laan2024dnamethylationepisignature pages 9-10). However, seven individuals with TCF4 variants exhibited negative episignatures, suggesting complexity related to mosaicism or genetic/environmental influences (laan2024dnamethylationepisignature pages 1-3).

5. Environmental Information

As a monogenic disorder caused by de novo germline mutations, PTHS has no established environmental risk factors, lifestyle factors, or infectious agents contributing to disease causation. Environmental and lifestyle modifications are relevant only in the context of supportive care and symptom management.

6. Mechanism / Pathophysiology

The following table summarizes the major molecular pathways disrupted in PTHS.

Pathway/Mechanism	Key Genes/Proteins	Effect of TCF4 Loss	Cell Types Affected	Therapeutic Relevance
Wnt/β-catenin signaling	SOX genes, Wnt7b	Decreased SOX expression and reduced neural progenitor proliferation; impaired neuronal differentiation and cortical neuron content	Neural progenitor cells	Pharmacologic Wnt pathway activation rescued patient-derived organoid/cellular phenotypes (savchenko2024transcriptionfactortcf4 pages 6-7, chen2021molecularandcellular pages 2-3)
SCN10A/Nav1.8 dysregulation	SCN10A (Nav1.8)	Ectopic upregulation, neuronal hyperexcitability, abnormal network synchrony, breathing abnormalities	Cortical neurons, parafacial neurons	Nav1.8 antagonists such as PF-04531083 normalized physiological and behavioral deficits in mouse models (martinowich2023evaluationofnav1.8 pages 3-5, martinowich2023evaluationofnav1.8 pages 1-2, cleary2021disorderedbreathingin pages 9-9)
Synaptic function (RIMBP2)	RIMBP2, GRIA1, DLG2, Nrxn1	Reduced glutamate release, impaired spontaneous synaptic transmission, disrupted network activity and plasticity	Cortical excitatory neurons	RIMBP2 restoration rescued synaptic and network deficits in patient-derived cortical neurons (davis2024tcf4mutationsdisrupt pages 1-3, davis2024tcf4mutationsdisrupt pages 11-12, chen2021molecularandcellular pages 2-3)
Neuronal migration	BMP7	Impaired cortical neuron positioning and migration; abnormal cortical development	Cortical pyramidal neurons	No established targeted therapy yet; pathway supports developmental mechanism studies (savchenko2024transcriptionfactortcf4 pages 8-9, chen2021molecularandcellular pages 3-4, hyojin2021preclinicaldevelopmentof pages 139-143)
Myelination	Plp1, Gjb2	Reduced oligodendrocyte density, dysmyelination, and myelin-related transcriptomic abnormalities	Oligodendrocytes	Pro-myelinating strategies including clemastine fumarate are being explored in preclinical models (martinowich2023evaluationofnav1.8 pages 3-5, savchenko2024transcriptionfactortcf4 pages 6-7, kim2022rescueofbehavioral pages 22-23, chen2021molecularandcellular pages 2-3)
Respiratory control	Phox2b, Atoh1	Loss of parafacial neurons, blunted CO2/H+ chemosensitivity, hyperventilation/apnea, prolonged post-sigh apnea	RTN chemoreceptors, pFL neurons	Nav1.8 blockade improved respiratory phenotypes in mice; acetazolamide has been used clinically for central apnea/breathing symptoms (cleary2021disorderedbreathingin pages 2-3, cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 3-4, cleary2021disorderedbreathingin pages 13-14)
Epigenetic regulation	HDAC-regulated pathways, DNA methylation loci	Altered DNA methylation episignature and epigenetic dysregulation; HDAC modulation can increase TCF4 expression	Multiple cell types	HDAC inhibitors are therapeutically relevant; vorinostat is in clinical testing and HDAC inhibition has been proposed to increase TCF4 expression (laan2024dnamethylationepisignature pages 4-7, laan2024dnamethylationepisignature pages 1-3, laan2024dnamethylationepisignature pages 9-10, NCT07150026 chunk 2, chen2021molecularandcellular pages 2-3)
MeCP2 pathway	MECP2	Decreased MeCP2 levels in PTHS patient-derived cells, with associated neural progenitor and astrocyte dysfunction	Neural progenitors, astrocytes	AAV9-MeCP2 gene therapy ameliorated histologic and behavioral phenotypes in mouse models (dennys2024mecp2genetherapy pages 1-2)

Table: This table summarizes major molecular pathways disrupted in Pitt-Hopkins syndrome, linking TCF4 loss to affected genes, cell types, and emerging therapeutic strategies. It is useful for quickly connecting pathophysiology with candidate interventions.

Detailed Pathophysiology

Wnt/β-catenin Pathway Disruption: TCF4 loss-of-function leads to decreased Wnt signaling, diminished SOX target gene expression, and reduced neural progenitor cell proliferation. This results in impaired neuronal differentiation and reduced cortical neuron content in patient-derived organoids, phenotypes that were rescued by pharmacological modulation of Wnt signaling (savchenko2024transcriptionfactortcf4 pages 6-7, chen2021molecularandcellular pages 2-3).

SCN10A/Nav1.8 Ectopic Upregulation: TCF4 normally represses SCN10A expression. Loss of TCF4 function results in ectopic overexpression of Nav1.8 in cortical neurons and brainstem neurons, leading to neuronal hyperexcitability, abnormal network synchronicity, and behavioral deficits (martinowich2023evaluationofnav1.8 pages 1-2, savchenko2024transcriptionfactortcf4 pages 6-7). The Nav1.8 antagonist PF-04531083 significantly reduced gamma event-related spectral perturbation and normalized intertrial coherence at theta and gamma frequencies (martinowich2023evaluationofnav1.8 pages 3-5).

RIMBP2-Mediated Synaptic Dysfunction: TCF4 mutations cause severe downregulation of RIMBP2, a presynaptic binding protein essential for coupling synaptic vesicles, calcium channels, and fusion machinery. This leads to reduced glutamate release, disrupted network activity, and impaired homeostatic plasticity. Restoring RIMBP2 expression rescued spontaneous network activity and normalized presynaptic glutamate release in patient-derived cortical neurons (davis2024tcf4mutationsdisrupt pages 1-3, davis2024tcf4mutationsdisrupt pages 11-12).

Respiratory Control Disruption: In the Tcf4tr/+ mouse model, there is selective loss of Phox2b-expressing parafacial neurons, with 70% fewer Phox2b+ neurons in the parafacial lateral (pFL) region and 21% reduction in the retrotrapezoid nucleus (RTN). These glutamatergic chemoreceptor neurons are critical for CO2/H+ sensing and breathing regulation. Their loss results in periodic breathing, hyperventilation episodes, reduced sigh frequency, prolonged post-sigh apnea, and absent active expiration responses to CO2 challenge (cleary2021disorderedbreathingin pages 2-3, cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 3-4, cleary2021disorderedbreathingin pages 4-5). Nav1.8 blockade improved multiple aspects of the respiratory phenotype (cleary2021disorderedbreathingin pages 8-9, cleary2021disorderedbreathingin pages 9-9).

Oligodendrocyte and Myelination Deficits: Transcriptional profiling revealed that differentially expressed genes in PTHS models are enriched in oligodendrocytes, with reduced oligodendrocyte density, myelination, and function. A myelin-related transcriptomic profile is shared between PTHS models and human ASD (martinowich2023evaluationofnav1.8 pages 3-5, kim2022rescueofbehavioral pages 22-23, chen2021molecularandcellular pages 7-8). TCF4 directly targets myelination-related genes including Plp1 and Gjb2 (chen2021molecularandcellular pages 2-3).

MeCP2 Pathway Convergence: MeCP2 levels are decreased in PTHS patient-derived induced neuronal progenitor cells. Genetic crossing of Tcf4+/− mice with MeCP2-overexpressing mice significantly ameliorated molecular and phenotypic defects, and postnatal AAV9-MeCP2 gene therapy improved histological and behavioral deficits (dennys2024mecp2genetherapy pages 1-2).

GO Terms for Key Biological Processes

GO:0007399 (nervous system development)
GO:0030182 (neuron differentiation)
GO:0042552 (myelination)
GO:0007268 (chemical synaptic transmission)
GO:0060079 (excitatory postsynaptic potential)
GO:0007420 (brain development)
GO:0007585 (respiratory gaseous exchange)

CL Terms for Key Cell Types

CL:0000540 (neuron)
CL:0000128 (oligodendrocyte)
CL:0000127 (astrocyte)
CL:0000047 (neuronal stem cell)
CL:0000617 (GABAergic neuron)

7. Anatomical Structures Affected

Organ Level

Primary: Central nervous system (brain), including cerebral cortex, hippocampus, corpus callosum, cerebellum/vermis, caudate nuclei (chen2021molecularandcellular pages 1-2)
Secondary: Respiratory system (brainstem respiratory centers), gastrointestinal tract, eyes, skeletal muscle (chiu2024skeletalmusclevulnerability pages 1-2, cleary2021disorderedbreathingin pages 1-2)

Tissue and Cell Level

Cortical gray matter (neurons, glial cells)
White matter (oligodendrocytes, myelinated axons)
Brainstem parafacial region (Phox2b+ chemoreceptor neurons) (cleary2021disorderedbreathingin pages 4-5)
Retinal tissue (contributing to myopia)
Skeletal muscle (fiber type I predominance, mitochondrial vulnerability) (chiu2024skeletalmusclevulnerability pages 1-2)

UBERON Terms

UBERON:0001890 (forebrain)
UBERON:0002421 (hippocampal formation)
UBERON:0002336 (corpus callosum)
UBERON:0001896 (medulla oblongata, containing RTN)
UBERON:0000955 (brain)

8. Temporal Development

Onset

PTHS typically presents in the first year of life with developmental delay (kim2022rescueofbehavioral pages 1-2). Onset is congenital/infantile. Diagnosis is generally made when infants fail to reach developmental milestones and undergo genetic testing, often at several years of age (james2025juvenilereinstatementof pages 1-5).

Progression

The condition is chronic and lifelong. Core neurodevelopmental features are stable (non-progressive) after the initial developmental period. Motor and speech regression occurs in approximately 6% of patients (zhao2024clinicalandgenetic pages 3-5). Mouse models show synaptic defects but no disease-related neurodegeneration, suggesting that observed defects could be reversible through genetic normalization approaches (kim2022rescueofbehavioral pages 1-2). However, juvenile reinstatement of TCF4 in mice largely fails to correct most phenotypes except cognitive function, revealing phenotype-specific plasticity and underscoring a narrow, early critical window for effective treatment (james2025juvenilereinstatementof pages 1-5).

9. Inheritance and Population

Inheritance Pattern

PTHS is inherited in an autosomal dominant manner, typically caused by de novo genetic alterations. Rare instances of parental mosaicism (germline mosaicism) have been reported (chen2021molecularandcellular pages 1-2). The condition shows complete penetrance for the core intellectual disability phenotype, though expressivity is variable for features such as seizures, breathing abnormalities, and facial features (chen2021molecularandcellular pages 1-2, zhao2024clinicalandgenetic pages 9-9). Boys and girls are affected equally (chiu2024skeletalmusclevulnerability pages 1-2).

Epidemiology

Prevalence estimates vary considerably: - 1 in 225,000 to 300,000 based on UK and Netherlands data (zhao2024clinicalandgenetic pages 1-2) - 1 in 34,000 to 41,000 births based on other estimates (chen2021molecularandcellular pages 1-2)

The discrepancy likely reflects underdiagnosis and ascertainment differences. Reliable figures for prevalence are not fully established (chen2021molecularandcellular pages 1-2). PTHS has been reported across diverse populations including European, Chinese, and other ethnicities, with no confirmed population-specific enrichment (zhao2024clinicalandgenetic pages 1-2, zhao2024clinicalandgenetic pages 7-9).

10. Diagnostics

Clinical Diagnosis

Clinical diagnosis is based on recognition of characteristic features including intellectual disability, facial gestalt, and breathing abnormalities, but accurate diagnosis requires genetic confirmation to rule out overlapping conditions such as Rett syndrome, Angelman syndrome, and Mowat-Wilson syndrome (chen2021molecularandcellular pages 1-2). Consensus diagnostic criteria exist but many features are not fully penetrant, complicating clinical recognition (chen2021molecularandcellular pages 1-2).

Genetic Testing

Whole exome sequencing (WES): Primary recommended approach; identifies point mutations and small indels (zhao2024clinicalandgenetic pages 3-5)
Gene panels: Intellectual disability/neurodevelopmental disorder panels including TCF4 (popp2022therecurrenttcf4 pages 2-3)
Chromosomal microarray (CMA): Detects deletions encompassing the TCF4 locus (~13% of cases) (zhao2024clinicalandgenetic pages 3-5)
MLPA: Used for confirmation of copy number aberrations (chiu2024skeletalmusclevulnerability pages 1-2)
Single gene testing: TCF4 sequencing and deletion/duplication analysis

Epigenomic Diagnostics

A DNA methylation episignature for PTHS has been developed using Infinium Methylation EPIC BeadChip array analysis on peripheral blood. An SVM classifier model exhibits high sensitivity for TCF4 loss-of-function variants and enables improved diagnostic accuracy and reclassification of variants of uncertain significance (VUS) (laan2024dnamethylationepisignature pages 1-3, laan2024dnamethylationepisignature pages 4-7). Negative episignature results do not exclude PTHS diagnosis due to factors such as mosaicism or genetic modifiers (laan2024dnamethylationepisignature pages 7-9).

Neuroimaging

Brain MRI reveals abnormalities in 79% of patients, including ventricle enlargement, wide extracranial space, and corpus callosum hypoplasia (zhao2024clinicalandgenetic pages 3-5). Underdevelopment of the corpus callosum, smaller hippocampus, enlarged caudate nuclei, and cerebellar/vermis hypoplasia have been reported (chen2021molecularandcellular pages 1-2).

Differential Diagnosis

Key conditions to differentiate include Rett syndrome (MECP2), Angelman syndrome (UBE3A), Mowat-Wilson syndrome (ZEB2), and Phelan-McDermid syndrome (SHANK3) (chen2021molecularandcellular pages 1-2, dennys2024mecp2genetherapy pages 1-2).

11. Outcome/Prognosis

Survival and Life Expectancy

Limited long-term survival data are available. PTHS is a chronic lifelong condition. There are no established disease-specific mortality data in the literature, though breathing abnormalities and epilepsy may contribute to complications. Adults with PTHS have been described, indicating survival into adulthood (NCT07135050 chunk 1).

Morbidity and Function

PTHS causes significant morbidity with severe intellectual disability, absent or minimal speech, motor impairments, and inability to live independently. Quality of life is substantially impacted, and affected individuals require lifelong care (zhao2024clinicalandgenetic pages 3-5, zhao2024clinicalandgenetic pages 2-3). Adaptive functioning is markedly impaired. Clinical trial outcome measures include QI-Disability, ICND overall quality of life rating, Vineland Adaptive Behavior Scales, and ORCA communication ability measures (NCT05025332 chunk 1, NCT05025332 chunk 2).

Prognostic Factors

No significant correlations between genotype and phenotype severity have been established in large cohorts, though mutations in the bHLH domain and exons 7–8 tend to correlate with more severe intellectual disability (zhao2024clinicalandgenetic pages 7-9, popp2022therecurrenttcf4 pages 2-3). Early intervention and rehabilitation may improve outcomes (zhao2024clinicalandgenetic pages 7-9).

12. Treatment

Current Management (Supportive/Symptomatic)

Currently, treatment of PTHS is entirely focused on managing symptoms, with no therapies targeting the underlying molecular pathology (dennys2024mecp2genetherapy pages 1-2). Supportive measures include: - Rehabilitation: Physical therapy, occupational therapy, speech therapy (MAXO:0000011, MAXO:0000497) - Antiepileptic medications: For seizure management - Ketogenic diet: Shows promising results for refractory epilepsy in PTHS (zhao2024clinicalandgenetic pages 7-9) - Acetazolamide: Used for breathing abnormalities/central apnea (cleary2021disorderedbreathingin pages 13-14) - Behavioral interventions: For ASD-associated behaviors

Clinical Trials

NCT Number	Trial Name	Intervention	Phase	Status	Enrollment	Sponsor	Year
NCT05025332	An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)	NNZ-2591 oral solution; cyclo-L-glycyl-L-2-allylproline	Phase 2	Completed	28	Neuren Pharmaceuticals Limited	2021–2025 (completed 2024) (NCT05025332 chunk 1, NCT05025332 chunk 2)
NCT07135050	Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome	MZ-1866 AAV-9 gene therapy; intracerebroventricular injection	Phase 1/2	Recruiting	12	Mahzi Therapeutics	2025–2029 est. (NCT07135050 chunk 1)
NCT07150026	An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome	Vorinostat; HDAC inhibitor	Phase 1	Recruiting	5	Unravel Biosciences, Inc.	2026 (NCT07150026 chunk 2)
NCT04132427	Microbiota Transfer Therapy for Children With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders	Microbiota transfer therapy: oral vancomycin, magnesium citrate, fecal microbiota/placebo	Phase 2	Completed	6	Arizona State University	2019–2024 (completed 2022) (NCT04132427 chunk 1)
NCT06321796	Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders	Microbiota Transfer Therapy (extension)	Phase 2	Unknown	20	Gut-Brain-Axis Therapeutics Inc.	2024 (OpenTargets Search: Pitt-Hopkins syndrome)
NCT05165017	Randomized Double Blind Placebo Controlled Study of the Safety & Efficacy of Therapeutic Treatment With AlloRx Stem Cells® in Patients With Pitt Hopkins Syndrome	AlloRx Stem Cells®; umbilical cord-derived allogeneic mesenchymal stem cells	Phase 1/2	Unknown / not yet recruiting at last update	26	Vitro Biopharma Inc.	2021–2023 est. (NCT05165017 chunk 1)

Table: This table summarizes currently identified Pitt-Hopkins syndrome interventional trials, including drug, gene therapy, microbiome, and cell therapy studies. It is useful for quickly comparing intervention types, development stage, recruitment status, and sponsor activity.

Experimental Therapeutics

Gene Therapy Approaches: MZ-1866 (NCT07135050) is an AAV-9 gene therapy delivered by intracerebroventricular injection currently in Phase 1/2 trials (NCT07135050 chunk 1). Preclinical studies demonstrated that postnatally reinstating Tcf4 expression in neurons improved anxiety-like behavior, activity levels, innate behaviors, memory, and partially corrected EEG abnormalities (kim2022rescueofbehavioral pages 1-2). However, juvenile reinstatement largely fails to correct most phenotypes, revealing a narrow early critical window for effective treatment (james2025juvenilereinstatementof pages 1-5).

HDAC Inhibitors: Vorinostat (NCT07150026) is being evaluated based on evidence that pharmacological inhibition of class I histone deacetylases increases TCF4 expression (NCT07150026 chunk 2, chen2021molecularandcellular pages 2-3).

Nav1.8 Antagonists: Preclinical studies show that blocking Nav1.8 with PF-04531083 normalizes neural synchrony, reduces hyperventilation episodes, and improves behavioral phenotypes in PTHS mouse models (martinowich2023evaluationofnav1.8 pages 3-5, cleary2021disorderedbreathingin pages 9-9).

Pro-myelinating Agents: Clemastine fumarate enhances myelination and promotes functional recovery in PTHS mouse models (savchenko2024transcriptionfactortcf4 pages 6-7).

MeCP2-Based Therapy: AAV9-MeCP2 gene therapy significantly improved neuronal progenitor cell and astrocyte function and ameliorated histological and behavioral defects in Tcf4+/− mice (dennys2024mecp2genetherapy pages 1-2).

13. Prevention

Primary Prevention

As PTHS results from de novo mutations, primary prevention is not applicable.

Genetic Counseling

Genetic counseling is recommended for families. Recurrence risk is generally low given the de novo nature, but parental mosaicism should be considered (chen2021molecularandcellular pages 1-2). Prenatal and preimplantation genetic testing is feasible if the family-specific TCF4 variant has been identified.

Screening

There are no population-based newborn screening programs for PTHS. Cascade genetic testing of family members may be indicated when parental mosaicism is suspected. The DNA methylation episignature can serve as a secondary screening/confirmation tool for individuals with suspected PTHS and VUS in TCF4 (laan2024dnamethylationepisignature pages 4-7, laan2024dnamethylationepisignature pages 10-11).

14. Other Species / Natural Disease

PTHS is a human-specific genetic condition caused by de novo TCF4 mutations. No naturally occurring disease analogous to PTHS has been documented in other species. However, TCF4 is evolutionarily conserved, with orthologous genes expressed in mice (Mus musculus, NCBI Taxon 10090), rats, and other vertebrates (chen2021molecularandcellular pages 1-2).

15. Model Organisms

Mouse Models

Multiple mouse models have been developed:

Tcf4STOP/+ (conditional model): Contains a loxP-flanked STOP cassette in exon 18, reducing full-length Tcf4 expression by approximately 50%. Recapitulates reduced body/brain weight (microcephaly), long-term memory deficits, increased locomotor activity, and impaired nest-building (kim2022rescueofbehavioral pages 2-4).
Tcf4tr/+ (truncation model): Expresses a truncated TCF4 protein. Displays frequent hyperventilation episodes, reduced sigh activity, prolonged post-sigh apnea, blunted ventilatory responses to CO2, and selective loss of parafacial Phox2b+ neurons (cleary2021disorderedbreathingin pages 2-3, cleary2021disorderedbreathingin pages 1-2, cleary2021disorderedbreathingin pages 4-5).
Tcf4+/− (heterozygous knockout, Jackson Laboratory stock 013598, B6;129-Tcf4tm1Zhu/J): Used extensively for behavioral, molecular, and gene therapy studies (dennys2024mecp2genetherapy pages 1-2).

Phenotype Recapitulation

Mouse models recapitulate key human PTHS symptoms including intellectual disability (memory deficits), motor delay (locomotor abnormalities), sleep disturbances, microcephaly, breathing disruption, hypotonia, seizures, reduced oligodendrocyte density and myelination, and synaptic dysfunction (james2025juvenilereinstatementof pages 1-5, martinowich2023evaluationofnav1.8 pages 3-5). A myelin-related transcriptomic profile is shared between five PTHS mouse models and human ASD (kim2022rescueofbehavioral pages 22-23).

iPSC-Derived Models

Patient-derived iPSC models include neural progenitor cells, cortical neurons, astrocytes, and brain organoids. These human cellular models demonstrate reduced progenitor proliferation, impaired neuronal differentiation, abnormal organoid size and cellular composition, reduced spontaneous synaptic transmission, and downregulated RIMBP2 expression (savchenko2024transcriptionfactortcf4 pages 6-7, davis2024tcf4mutationsdisrupt pages 1-3, dennys2024mecp2genetherapy pages 1-2).

Research Applications and Limitations

These models have been used for testing therapeutic interventions including HDAC inhibitors, Nav1.8 antagonists, Tcf4 gene reinstatement, MeCP2 gene therapy, and clemastine fumarate (savchenko2024transcriptionfactortcf4 pages 6-7, kim2022rescueofbehavioral pages 1-2). A critical finding from juvenile reinstatement studies is that delayed intervention largely fails to correct most phenotypes except cognitive function, underscoring a narrow early critical window for effective genetic treatment (james2025juvenilereinstatementof pages 1-5).

Summary

Pitt-Hopkins syndrome is a rare monogenic neurodevelopmental disorder caused by haploinsufficiency of TCF4, a bHLH transcription factor critical for brain development. The disease manifests with severe intellectual disability, characteristic facial features, breathing abnormalities, and motor impairments. Molecular studies have revealed that TCF4 regulates multiple downstream pathways including Wnt/β-catenin signaling, SCN10A/Nav1.8 expression, RIMBP2-mediated synaptic function, and oligodendrocyte myelination. A DNA methylation episignature enables improved diagnostic classification. The therapeutic landscape is rapidly evolving, with an AAV-9 gene therapy (NCT07135050), HDAC inhibitor vorinostat (NCT07150026), and NNZ-2591 (NCT05025332, completed) in clinical trials (OpenTargets Search: Pitt-Hopkins syndrome, NCT07135050 chunk 1, NCT07150026 chunk 2, NCT05025332 chunk 1). Preclinical studies support genetic normalization strategies but underscore the importance of early intervention timing (james2025juvenilereinstatementof pages 1-5, kim2022rescueofbehavioral pages 1-2).

References

(chen2021molecularandcellular pages 1-2): Huei-Ying Chen, Joseph F. Bohlen, and Brady J. Maher. Molecular and cellular function of transcription factor 4 in pitt-hopkins syndrome. Developmental Neuroscience, 43:159-167, Jun 2021. URL: https://doi.org/10.1159/000516666, doi:10.1159/000516666. This article has 34 citations and is from a peer-reviewed journal.
(sweetser2025pitthopkinssyndrome pages 1-1): DA Sweetser, KS Gipson, and C Zar-Kessler. Pitt-hopkins syndrome. Definitions, Feb 2025. URL: https://doi.org/10.4135/9781483392271.n390, doi:10.4135/9781483392271.n390. This article has 58 citations.
(martinowich2023evaluationofnav1.8 pages 1-2): Keri Martinowich, Debamitra Das, Srinidhi Rao Sripathy, Yishan Mai, Rakaia F. Kenney, and Brady J. Maher. Evaluation of nav1.8 as a therapeutic target for pitt hopkins syndrome. Molecular Psychiatry, 28:76-82, Oct 2023. URL: https://doi.org/10.1038/s41380-022-01811-4, doi:10.1038/s41380-022-01811-4. This article has 16 citations and is from a highest quality peer-reviewed journal.
(zhao2024clinicalandgenetic pages 1-2): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.
(jiang2024agenotypicand pages 1-2): Dandan Jiang, Chengqing Yang, Mei Hou, Dianrong Sun, Danni Jiang, and Zongbo Chen. A genotypic and phenotypic analysis of four unrelated chinese patients with pitt–hopkins syndrome. Egyptian Journal of Medical Human Genetics, Oct 2024. URL: https://doi.org/10.1186/s43042-024-00586-3, doi:10.1186/s43042-024-00586-3. This article has 1 citations and is from a peer-reviewed journal.
(OpenTargets Search: Pitt-Hopkins syndrome): Open Targets Query (Pitt-Hopkins syndrome, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(chen2021molecularandcellular pages 2-3): Huei-Ying Chen, Joseph F. Bohlen, and Brady J. Maher. Molecular and cellular function of transcription factor 4 in pitt-hopkins syndrome. Developmental Neuroscience, 43:159-167, Jun 2021. URL: https://doi.org/10.1159/000516666, doi:10.1159/000516666. This article has 34 citations and is from a peer-reviewed journal.
(popp2022therecurrenttcf4 pages 2-3): Bernt Popp, Thierry Bienvenu, Irina Giurgea, Julia Metreau, Cornelia Kraus, André Reis, Jan Fischer, María Palomares Bralo, Jair Tenorio‐Castaño, Pablo Lapunzina, Berta Almoguera, Fermina Lopez‐Grondona, Heinrich Sticht, and Christiane Zweier. The recurrent tcf4 missense variant p.(arg389cys) causes a neurodevelopmental disorder overlapping with but not typical for pitt‐hopkins syndrome. Clinical Genetics, 102:517-523, Aug 2022. URL: https://doi.org/10.1111/cge.14206, doi:10.1111/cge.14206. This article has 7 citations and is from a peer-reviewed journal.
(chiu2024skeletalmusclevulnerability pages 1-2): Celine Chiu, Alma Küchler, Christel Depienne, Corinna Preuße, Adela Della Marina, Andre Reis, Frank J. Kaiser, Kay Nolte, Andreas Hentschel, Ulrike Schara-Schmidt, Heike Kölbel, and Andreas Roos. Skeletal muscle vulnerability in a child with pitt-hopkins syndrome. Skeletal Muscle, Jul 2024. URL: https://doi.org/10.1186/s13395-024-00348-0, doi:10.1186/s13395-024-00348-0. This article has 1 citations and is from a peer-reviewed journal.
(zhao2024clinicalandgenetic pages 3-5): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.
(zhao2024clinicalandgenetic pages 7-9): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.
(zhao2024clinicalandgenetic pages 2-3): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.
(cleary2021disorderedbreathingin pages 2-3): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.
(cleary2021disorderedbreathingin pages 1-2): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.
(cleary2021disorderedbreathingin pages 9-9): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.
(dennys2024mecp2genetherapy pages 1-2): Cassandra N. Dennys, Sheryl Anne D. Vermudez, Robert J.M. Deacon, J. Andrea Sierra-Delgado, Kelly Rich, Xiaojin Zhang, Aditi Buch, Kelly Weiss, Yuta Moxley, Hemangi Rajpal, Francisca D. Espinoza, Samantha Powers, Ariel S. Ávila, Rocco G. Gogliotti, Patricia Cogram, Colleen M. Niswender, and Kathrin C. Meyer. Mecp2 gene therapy ameliorates disease phenotype in mouse model for pitt hopkins syndrome. Neurotherapeutics, 21:e00376, Sep 2024. URL: https://doi.org/10.1016/j.neurot.2024.e00376, doi:10.1016/j.neurot.2024.e00376. This article has 7 citations and is from a peer-reviewed journal.
(james2025juvenilereinstatementof pages 1-5): Lucas M. James, Carlee A. Friar, Siyuan Liang, Eric B. Gao, Alain. C. Burette, and Benjamin D. Philpot. Juvenile reinstatement of tcf4 in pitt-hopkins syndrome model mice reveals a critical window for genetic intervention. bioRxiv, Dec 2025. URL: https://doi.org/10.64898/2025.12.23.696277, doi:10.64898/2025.12.23.696277. This article has 0 citations.
(popp2022therecurrenttcf4 pages 7-7): Bernt Popp, Thierry Bienvenu, Irina Giurgea, Julia Metreau, Cornelia Kraus, André Reis, Jan Fischer, María Palomares Bralo, Jair Tenorio‐Castaño, Pablo Lapunzina, Berta Almoguera, Fermina Lopez‐Grondona, Heinrich Sticht, and Christiane Zweier. The recurrent tcf4 missense variant p.(arg389cys) causes a neurodevelopmental disorder overlapping with but not typical for pitt‐hopkins syndrome. Clinical Genetics, 102:517-523, Aug 2022. URL: https://doi.org/10.1111/cge.14206, doi:10.1111/cge.14206. This article has 7 citations and is from a peer-reviewed journal.
(zhao2024clinicalandgenetic pages 9-9): Tingting Zhao, Shengnan Wu, Yiping Shen, Jing Leng, Georgi Z. Genchev, Hui Lu, and Jincai Feng. Clinical and genetic characterization of 47 chinese pediatric patients with pitt–hopkins syndrome: a retrospective study. Orphanet Journal of Rare Diseases, Feb 2024. URL: https://doi.org/10.1186/s13023-024-03055-7, doi:10.1186/s13023-024-03055-7. This article has 4 citations and is from a peer-reviewed journal.
(laan2024dnamethylationepisignature pages 1-3): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.
(laan2024dnamethylationepisignature pages 7-9): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.
(laan2024dnamethylationepisignature pages 9-10): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.
(savchenko2024transcriptionfactortcf4 pages 6-7): R. R. Savchenko and N. A. Skryabin. Transcription factor tcf4: structure, function, and associated diseases. Vavilov Journal of Genetics and Breeding, 28:770-779, Nov 2024. URL: https://doi.org/10.18699/vjgb-24-85, doi:10.18699/vjgb-24-85. This article has 5 citations.
(martinowich2023evaluationofnav1.8 pages 3-5): Keri Martinowich, Debamitra Das, Srinidhi Rao Sripathy, Yishan Mai, Rakaia F. Kenney, and Brady J. Maher. Evaluation of nav1.8 as a therapeutic target for pitt hopkins syndrome. Molecular Psychiatry, 28:76-82, Oct 2023. URL: https://doi.org/10.1038/s41380-022-01811-4, doi:10.1038/s41380-022-01811-4. This article has 16 citations and is from a highest quality peer-reviewed journal.
(davis2024tcf4mutationsdisrupt pages 1-3): Brittany A. Davis, Huei-Ying Chen, Zengyou Ye, Isaac Ostlund, Madhavi Tippani, Debamitra Das, Srinidhi Rao Sripathy, Yanhong Wang, Jacqueline M. Martin, Gina Shim, Neel M. Panchwagh, Rebecca L. Moses, Federica Farinelli, Joseph F. Bohlen, Meijie Li, Bryan W. Luikart, Andrew E. Jaffe, and Brady J. Maher. Tcf4 mutations disrupt synaptic function through dysregulation of rimbp2 in patient-derived cortical neurons. Biological Psychiatry, 95:662-675, Apr 2024. URL: https://doi.org/10.1016/j.biopsych.2023.07.021, doi:10.1016/j.biopsych.2023.07.021. This article has 19 citations and is from a highest quality peer-reviewed journal.
(davis2024tcf4mutationsdisrupt pages 11-12): Brittany A. Davis, Huei-Ying Chen, Zengyou Ye, Isaac Ostlund, Madhavi Tippani, Debamitra Das, Srinidhi Rao Sripathy, Yanhong Wang, Jacqueline M. Martin, Gina Shim, Neel M. Panchwagh, Rebecca L. Moses, Federica Farinelli, Joseph F. Bohlen, Meijie Li, Bryan W. Luikart, Andrew E. Jaffe, and Brady J. Maher. Tcf4 mutations disrupt synaptic function through dysregulation of rimbp2 in patient-derived cortical neurons. Biological Psychiatry, 95:662-675, Apr 2024. URL: https://doi.org/10.1016/j.biopsych.2023.07.021, doi:10.1016/j.biopsych.2023.07.021. This article has 19 citations and is from a highest quality peer-reviewed journal.
(savchenko2024transcriptionfactortcf4 pages 8-9): R. R. Savchenko and N. A. Skryabin. Transcription factor tcf4: structure, function, and associated diseases. Vavilov Journal of Genetics and Breeding, 28:770-779, Nov 2024. URL: https://doi.org/10.18699/vjgb-24-85, doi:10.18699/vjgb-24-85. This article has 5 citations.
(chen2021molecularandcellular pages 3-4): Huei-Ying Chen, Joseph F. Bohlen, and Brady J. Maher. Molecular and cellular function of transcription factor 4 in pitt-hopkins syndrome. Developmental Neuroscience, 43:159-167, Jun 2021. URL: https://doi.org/10.1159/000516666, doi:10.1159/000516666. This article has 34 citations and is from a peer-reviewed journal.
(hyojin2021preclinicaldevelopmentof pages 139-143): Preclinical Development of Genetic Normalization Strategies to Treat Pitt-Hopkins Syndrome This article has 0 citations and is from a peer-reviewed journal.
(kim2022rescueofbehavioral pages 22-23): Hyojin Kim, Eric B. Gao, Adam Draper, Noah C. Berens, Hanna Vihma, Xinyuan Zhang, Alexandra Higashi-Howard, Kimberly D. Ritola, Jeremy M. Simon, Andrew J. Kennedy, and Benjamin D. Philpot. Rescue of behavioral and electrophysiological phenotypes in a pitt-hopkins syndrome mouse model by genetic restoration of tcf4 expression. eLife, Aug 2022. URL: https://doi.org/10.7554/elife.72290, doi:10.7554/elife.72290. This article has 29 citations and is from a domain leading peer-reviewed journal.
(cleary2021disorderedbreathingin pages 3-4): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.
(cleary2021disorderedbreathingin pages 13-14): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.
(laan2024dnamethylationepisignature pages 4-7): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.
(NCT07150026 chunk 2): An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome. Unravel Biosciences, Inc.. 2026. ClinicalTrials.gov Identifier: NCT07150026
(cleary2021disorderedbreathingin pages 4-5): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.
(cleary2021disorderedbreathingin pages 8-9): C. M. Cleary, S. James, B. J. Maher, and D. K. Mulkey. Disordered breathing in a pitt-hopkins syndrome model involves phox2b-expressing parafacial neurons and aberrant nav1.8 expression. Nature Communications, Oct 2021. URL: https://doi.org/10.1038/s41467-021-26263-2, doi:10.1038/s41467-021-26263-2. This article has 22 citations and is from a highest quality peer-reviewed journal.
(chen2021molecularandcellular pages 7-8): Huei-Ying Chen, Joseph F. Bohlen, and Brady J. Maher. Molecular and cellular function of transcription factor 4 in pitt-hopkins syndrome. Developmental Neuroscience, 43:159-167, Jun 2021. URL: https://doi.org/10.1159/000516666, doi:10.1159/000516666. This article has 34 citations and is from a peer-reviewed journal.
(kim2022rescueofbehavioral pages 1-2): Hyojin Kim, Eric B. Gao, Adam Draper, Noah C. Berens, Hanna Vihma, Xinyuan Zhang, Alexandra Higashi-Howard, Kimberly D. Ritola, Jeremy M. Simon, Andrew J. Kennedy, and Benjamin D. Philpot. Rescue of behavioral and electrophysiological phenotypes in a pitt-hopkins syndrome mouse model by genetic restoration of tcf4 expression. eLife, Aug 2022. URL: https://doi.org/10.7554/elife.72290, doi:10.7554/elife.72290. This article has 29 citations and is from a domain leading peer-reviewed journal.
(NCT07135050 chunk 1): Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome. Mahzi Therapeutics. 2025. ClinicalTrials.gov Identifier: NCT07135050
(NCT05025332 chunk 1): An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001). Neuren Pharmaceuticals Limited. 2022. ClinicalTrials.gov Identifier: NCT05025332
(NCT05025332 chunk 2): An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001). Neuren Pharmaceuticals Limited. 2022. ClinicalTrials.gov Identifier: NCT05025332
(NCT04132427 chunk 1): MTT for Children With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders. Arizona State University. 2019. ClinicalTrials.gov Identifier: NCT04132427
(NCT05165017 chunk 1): Safety & Efficacy of AlloRx SC® in PTHS Patients. Vitro Biopharma Inc.. 2021. ClinicalTrials.gov Identifier: NCT05165017
(laan2024dnamethylationepisignature pages 10-11): Liselot van der Laan, Peter Lauffer, Kathleen Rooney, Ananília Silva, Sadegheh Haghshenas, Raissa Relator, Michael A. Levy, Slavica Trajkova, Sylvia A. Huisman, Emilia K. Bijlsma, Tjitske Kleefstra, Bregje W. van Bon, Özlem Baysal, Christiane Zweier, María Palomares-Bralo, Jan Fischer, Katalin Szakszon, Laurence Faivre, Amélie Piton, Simone Mesman, Ron Hochstenbach, Mariet W. Elting, Johanna M. van Hagen, Astrid S. Plomp, Marcel M.A.M. Mannens, Mariëlle Alders, Mieke M. van Haelst, Giovanni B. Ferrero, Alfredo Brusco, Peter Henneman, David A. Sweetser, Bekim Sadikovic, Antonio Vitobello, and Leonie A. Menke. Dna methylation episignature and comparative epigenomic profiling for pitt-hopkins syndrome caused by tcf4 variants. Human Genetics and Genomics Advances, 5:100289, Jul 2024. URL: https://doi.org/10.1016/j.xhgg.2024.100289, doi:10.1016/j.xhgg.2024.100289. This article has 7 citations and is from a peer-reviewed journal.
(kim2022rescueofbehavioral pages 2-4): Hyojin Kim, Eric B. Gao, Adam Draper, Noah C. Berens, Hanna Vihma, Xinyuan Zhang, Alexandra Higashi-Howard, Kimberly D. Ritola, Jeremy M. Simon, Andrew J. Kennedy, and Benjamin D. Philpot. Rescue of behavioral and electrophysiological phenotypes in a pitt-hopkins syndrome mouse model by genetic restoration of tcf4 expression. eLife, Aug 2022. URL: https://doi.org/10.7554/elife.72290, doi:10.7554/elife.72290. This article has 29 citations and is from a domain leading peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Pathophysiology

Phenotypes

Genetic Associations

Medical Actions

Differential Diagnoses

Source YAML

References & Deep Research

Deep Research

1. Disease Information

Overview

Key Identifiers

Synonyms and Alternative Names

2. Etiology

Disease Causal Factors

Genetic Risk Factors

Environmental and Protective Factors

3. Phenotypes

Detailed Phenotype Characteristics

Age of Onset and Progression

4. Genetic/Molecular Information

Causal Gene

Pathogenic Variants

Epigenetic Information

5. Environmental Information

6. Mechanism / Pathophysiology

Detailed Pathophysiology

GO Terms for Key Biological Processes

CL Terms for Key Cell Types

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

UBERON Terms

8. Temporal Development

Onset

Progression

9. Inheritance and Population

Inheritance Pattern

Epidemiology

10. Diagnostics

Clinical Diagnosis

Genetic Testing

Epigenomic Diagnostics

Neuroimaging

Differential Diagnosis

11. Outcome/Prognosis

Survival and Life Expectancy

Morbidity and Function

Prognostic Factors

12. Treatment

Current Management (Supportive/Symptomatic)

Clinical Trials

Experimental Therapeutics

13. Prevention

Primary Prevention

Genetic Counseling

Screening

14. Other Species / Natural Disease

15. Model Organisms

Mouse Models

Phenotype Recapitulation

iPSC-Derived Models

Research Applications and Limitations

Summary

Artifacts